SCHEMBL10283350

SCHEMBL10283350

Ic1cnc2c(c1)CCN2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 4/20 0.53
GRM5 P41594 2/20 0.50
ASIC3 Q9UHC3 1/20 0.47
PIK3C3 Q8NEB9 1/20 0.40
FEN1 P39748 4/20 0.38
ALOX5AP P20292 3/20 0.38
PIK3CD O00329 1/20 0.36
ADRA2A P08913 1/20 0.36
PNMT P11086 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
ADORA2A P29274 1/20 0.34
ABL1 P00519 1/20 0.34
CHRNB2 P17787 2/20 0.33
CHRNA4 P43681 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258214 0.89 NNMT (0.55) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL8385272 0.76 NNMT (0.53) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL13004722 0.76 NNMT (0.53) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL298258 0.76 NNMT (0.53) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL13538508 0.76 NNMT (0.53) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL13154323 0.76 NNMT (0.57) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL1723715 0.76 NNMT (0.53) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL828125 0.76 NNMT (0.53) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL21573715 0.76 NNMT (0.57) NNMTGRM5ASIC3PIK3C3FEN1
SCHEMBL18307148 0.76 GRM5 (0.54) NNMTGRM5FEN1ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022166920-A1 PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 杭州中美华东制药有限公司 2022-08-11 WO disclosed
EP-3901153-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2021-10-27 EP disclosed
EP-3288940-B9 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 EP disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF NNMT 4131/4885GRM5 3379/4885ASIC3 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.